Thrombophilia testing is a critical aspect of managing venous thromboembolism, a condition affecting approximately 1 in 1000 individuals annually and causing significant morbidity, mortality, and health care costs. This document provides an in-depth overview of current best practices in thrombophilia testing, including clinical guidelines, assay methodologies, and advances in molecular diagnostics, with the aim of optimizing diagnosis, treatment, and prevention strategies.
The landscape of hemophilia treatment has recently undergone a drastic transformation with the advent of novel therapies, including extended half-life factor concentrates, nonfactor therapies, rebalancing agents, and gene therapies. While these advancements have improved patient outcomes, they have introduced challenges in laboratory monitoring. Traditional assays such as prothrombin time, activated partial thromboplastin time, and 1-stage clotting assays may not accurately reflect the hemostatic status in patients receiving these new treatments. This article reviews the evolution of hemophilia therapies and the corresponding challenges in laboratory testing, emphasizing the need for updated monitoring strategies to ensure optimal patient management.
Direct thrombin inhibitors (DTIs) such as bivalirudin and argatroban have a predictable anticoagulant response, the ability to inhibit thrombin bound to fibrin, and efficacy in thrombotic environments. These properties make them a valuable tool to manage patients at risk of thrombotic events. DTIs require less frequent monitoring and dose adjustments than heparin. Due to poor correlation of activated partial thromboplastin time with DTI concentration, diluted thrombin time is widely used for monitoring bivalirudin anticoagulation. Emerging monitoring methods are promising and reflect the evolution of precision medicine toward more personalized, real-time monitoring techniques that can guide anticoagulation therapy in complex cases.
